×

Financial engineering 'sucking money out of R&D': UTHR CEO

7:34 AM ET Thu, 7 April 2016

Martine Rothblatt, United Therapeutics, weighs in on why the Treasury's tax inversion rule in good for big pharma. If the corporate tax rate was dropped in the U.S. then there would be no reason for inversions to go on, says Rothblatt.